Prevention of type 1 diabetes mellitus using a novel vaccine

Therapeutic Advances in Endocrinology and Metabolism

Volumn 2, Issue 1, 2011, Pages 9-16

  Orban, Tihamer ^a   Kis, Janos Tibor ^b  

^a JOSLIN DIABETES CENTER   (United States)

^b Polyclinic of the Hospitaller Brothers of St John ^*  (Hungary)

Author keywords

immunology; regulatory cells; type 1 diabetes mellitus; vaccine

Indexed keywords

ANTIDIABETIC AGENT; AZATHIOPRINE; BOVINE SERUM ALBUMIN; CYCLOSPORIN; FREUND ADJUVANT; GLUCOCORTICOID; HEAT SHOCK PROTEIN; IBC VS 01; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INSULIN; INSULIN B CHAIN; INSULIN B CHAIN VACCINE; NBI 6024; NICOTINAMIDE; OTELIXIZUMAB; PLACEBO; PROTEIN P277 DIAPEP; RECOMBINANT ALPHA INTERFERON; RITUXIMAB; TACROLIMUS; TRANSGENIC GLUTAMATE DECARBOXYLASE 65; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNITY; B CELL LYMPHOMA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIABETOGENESIS; DIET THERAPY; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FLU LIKE SYNDROME; HIGH RISK POPULATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INJECTION SITE DISCOMFORT; INJECTION SITE PAIN; INSULIN DEPENDENT DIABETES MELLITUS; LIVER TOXICITY; MACROPHAGE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PLASMAPHERESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SIDE EFFECT; STEROID DIABETES; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 79960032138     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018810390546     Document Type: Review

References (47)

1. Agardh C.D. Cilio C.M. Lethagen A. Lynch K. Leslie R.D. Palmer M. et al (2005) Clinical evidence for the safety of GAD 65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 19: 238–246.
2. Barker J.M. McFann K.K. Orban T. (2007) Effect of oral insulin on insulin autoantibody levels in the Diabetes Prevention Trial Type 1 oral insulin study. Diabetologia 50: 1603–1606.
3. Bluestone J.A. Tang Q. Sedwick C.E. (2008) T regulatory cells in autoimmune diabetes: Past challenges, future prospects. J Clin Immunol 28: 677–684.
4. Brod S.A. Atkinson M. Lavis V.R. Brosnan P.G. Hardin D.S. Orlander P.R. et al (2001) Ingested IFN-alpha preserves residual beta cell function in type 1 diabetes. J Interferon Cytokine Res 21: 1021–1030.
5. Chatenoud L. (2010) Immune therapy for type 1 diabetes mellitus – what is unique about anti-CD3 antibodies? Nat Rev Endocrinol 6: 149–157.
6. Colagiuri S. Leong G.M. Thayer Z. Antony G. Dwyer J.M. Kidson W. et al (1996) Intravenous immunoglobulin therapy for autoimmune diabetes mellitus. Clin Exp Rheumatol 14(Suppl 15): S93–S97.
7. Fuchtenbusch M. Rabl W. Grassl B. Bachmann W. Standl E. Ziegler A.G. (1998) Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: The Schwabing Insulin Prophylaxis Pilot Trial. Diabetologia 41: 536–541.
8. Gale E.A. Bingley P.J. Emmett C.L. Collier T. (2004) European Nicotinamide Diabetes Intervention Trial (ENDIT): A randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 363: 925–931.
9. Gianani R. Campbell-Thompson M. Sarkar S.A. Wasserfall C. Pugliese A. Solis J.M. et al (2010) Dimorphic histopathology of long-standing childhood-onset diabetes. Diabetologia 53: 690–698.
10. Godfrey D.I. MacDonald H.R. Kronenberg M. Smyth M.J. van Kaer L. (2004) NKT cells: What's in a name? Nat Rev Immunol 4: 231–237.
11. Herold K.C. Gitelman S.E. Masharani U. Hagopian W. Bisikirska B. Donaldson D. et al (2005) A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54: 1763–1769.
12. Hovorka R. (2006) Continuous glucose monitoring and closed-loop systems. Diabet Med 23: 1–12.
13. Kent S.C. Chen Y. Bregoli L. Clemmings S.M. Kenyon N.S. Ricordi C. et al (2005 a) Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 435: 224–228.
14. Kent S.C. Chen Y. Clemmings S.M. Viglietta V. Kenyon N.S. Ricordi C. et al (2005 b) Loss of IL-4 secretion from human type 1a diabetic pancreatic draining lymph node NKT cells. J Immunol 175: 4458–4464.
15. Keymeulen B. Candon S. Fafi-Kremer S. Ziegler A. Leruez-Ville M. Mathieu C. et al (2010 a) Transient Epstein-Barr virus reactivation in CD 3 monoclonal antibody-treated patients. Blood 115: 1145–1155.
16. Keymeulen B. Vandemeulebroucke E. Ziegler A.G. Mathieu C. Kaufman L. Hale G. et al (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352: 2598–2608.
17. Keymeulen B. Walter M. Mathieu C. Kaufman L. Gorus F. Hilbrands R. et al (2010 b) Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53: 614–623.
18. Kis J. Engelmann P. Farkas K. Richman G. Eck S. Lolley J. et al (2007) Reduced CD4+ subset and Th 1 bias of the human iNKT cells in type 1 diabetes mellitus. J Leukoc Biol 81: 654–662.
19. Kulmala P. (2003) Prediabetes in children: Natural history, diagnosis, and preventive strategies. Paediatr Drugs 5: 211–221.
20. Lee P.T. Putnam A. Benlagha K. Teyton L. Gottlieb P.A. Bendelac A. (2002) Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 110: 793–800.
21. Liu E. Abiru N. Moriyama H. Miao D. Eisenbarth G.S. (2002) Induction of insulin autoantibodies and protection from diabetes with subcutaneous insulin B:9–23 peptide without adjuvant. Ann N Y Acad Sci 958: 224–227.
22. Ludvigsson J. Heding L. Lieden G. Marner B. Lernmark A. (1983) Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children. Br Med J (Clin Res Ed) 286: 176–178.
23. Martin S. Wolf-Eichbaum D. Duinkerken G. Scherbaum W.A. Kolb H. Noordzij J.G. et al (2001) Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 345: 1036–1040.
24. Monetini L. Cavallo M.G. Sarugeri E. Sentinelli F. Stefanini L. Bosi E. et al (2004) Cytokine profile and insulin antibody IgG subclasses in patients with recent onset type 1 diabetes treated with oral insulin. Diabetologia 47: 1795–1802.
25. Nakayama M. Abiru N. Moriyama H. Babaya N. Liu E. Miao D. et al (2005) Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435: 220–223.
26. Orban T. Farkas K. Jalahej H. Kis J. Treszl A. Falk B. et al (2010) Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun 34: 408–415.
27. Orban T. Kis J. Szereday L. Engelmann P. Farkas K. Jalahej H. et al (2007) Reduced CD4+ T-cell-specific gene expression in human type 1 diabetes mellitus. J Autoimmun 28: 177–187.
28. Orban T. Sosenko J.M. Cuthbertson D. Krischer J.P. Skyler J.S. Jackson R. et al (2009) Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 32: 2269–2274.
29. Panczel P. Hosszufalusi N. Bornemisza B. Horvath L. Janoskuti L. Fust G. et al (2001) Latent autoimmune diabetes in adults (LADA): Part of the clinical spectrum of type-1 diabetes mellitus of autoimmune origin. Orv Hetil 142: 2571–2578.
30. Patterson C.C. Dahlquist G.G. Gyurus E. Green A. Soltesz G. (2009) Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: A multicentre prospective registration study. Lancet 373: 2027–2033.
31. Perosa F. Favoino E. Caragnano M.A. Prete M. Dammacco F. (2005) CD20: A target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev 4: 526–531.
32. Pescovitz M.D. Greenbaum C.J. Krause-Steinrauf H. Becker D.J. Gitelman S.E. Goland R. et al (2009) Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 361: 2143–2152.
33. Petrovsky N. Silva D. Schatz D.A. (2003) Vaccine therapies for the prevention of type 1 diabetes mellitus. Paediatr Drugs 5: 575–582.
34. Quinn A. (2009) Are T-cell responses to GAD 65 influential in type 1 diabetes? Diabetes 58: 2729–2730.
35. Raz I. Eldor R. Naparstek Y. (2005) Immune modulation for prevention of type 1 diabetes mellitus. Trends Biotechnol 23: 128–134.
36. Schatz D.A. Bingley P.J. (2001) Update on major trials for the prevention of type 1 diabetes mellitus: The American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT). J Pediatr Endocrinol Metab 14(Suppl 1): 619–622.
37. Serreze D.V. Chen Y.G. (2005) Of mice and men: Use of animal models to identify possible interventions for the prevention of autoimmune type 1 diabetes in humans. Trends Immunol 26: 603–607.
38. Singh N. Palmer J.P. (2005) Therapeutic targets for the prevention of type 1 diabetes mellitus. Curr Drug Targets Immune Endocr Metabol Disord 5: 227–236.
39. Skyler J.S. Krischer J.P. Wolfsdorf J. Cowie C. Palmer J.P. Greenbaum C. et al (2005) Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial – Type 1. Diabetes Care 28: 1068–1076.
40. Vaziri-Sani, F., Oak, S., Radtke, J., Lernmark, A., Lynch, K., Agardh, C.D. et al (2010) ZnT 8 autoantibody titers in type 1 diabetes patients decline rapidly after clinical onset. Autoimmunity, Epub ahead of print.
41. Viskari H. Ludvigsson J. Uibo R. Salur L. Marciulionyte D. Hermann R. et al (2005) Relationship between the incidence of type 1 diabetes and maternal enterovirus antibodies: Time trends and geographical variation. Diabetologia 48: 1280–1287.
42. Walter M. Philotheou A. Bonnici F. Ziegler A.G. Jimenez R. (2009) No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes. Diabetes Care 32: 2036–2040.
43. Wenzlau J.M. Frisch L.M. Gardner T.J. Sarkar S. Hutton J.C. Davidson H.W. (2009) Novel antigens in type 1 diabetes: The importance of ZnT8. Curr Diab Rep 9: 105–112.
44. Wilson D.M. Buckingham B. (2001) Prevention of type 1a diabetes mellitus. Pediatr Diabetes 2: 17–24.
45. Wilson S.B. Kent S.C. Patton K.T. Orban T. Jackson R.A. Exley M. et al (1998) Extreme Th 1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature 391: 177–181.
46. Winter W.E. Schatz D. (2003) Prevention strategies for type 1 diabetes mellitus: Current status and future directions. BioDrugs 17: 39–64.
47. Wong F.S. (2005) Insulin – a primary autoantigen in type 1 diabetes? Trends Mol Med 11: 445–448.